Randomized Phase 2 Study of Erdafitinib vs Investigator Choice of Chemo in Subjects Who Received BCG and Recurred With HR NMIBC (42756493BLC2003) | NYU Langone Health

Go Back to All Clinical Trials

Randomized Phase 2 Study of Erdafitinib vs Investigator Choice of Chemo in Subjects Who Received BCG and Recurred With HR NMIBC (42756493BLC2003)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Bladder Cancer
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1) Histologically confirmed, recurrent, non-muscle-invasive urothelial carcinoma of the bladder. 2) Eastern Cooperative Oncology Group (ECOG) performance status Grade 0 or 1.

You may not be eligible for this study if the following are true:

1) Histologically confirmed, muscle-invasive (T2 or higher stage) urothelial carcinoma of the bladder. 2) Histopathology demonstrating any small cell component, pure adenocarcinoma, pure squamous cell carcinoma, or pure squamous CIS of the bladder. 3) Prior treatment with an FGFR inhibitor. 4) Active malignancies (ie, progressing or requiring treatment change in the last 24 months) other than the disease being treated under study.